Your browser doesn't support javascript.
loading
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19.
Elmunzer, B Joseph; Palsson, Olafur S; Forbes, Nauzer; Zakaria, Ali; Davis, Christian; Canakis, Andrew; Qayed, Emad; Bick, Benjamin; Pawa, Swati; Tierney, William M; McLeod, Caroline G; Taylor, Jason; Patel, Harsh; Mendelsohn, Robin B; Bala, Gokul; Sloan, Ian; Merchant, Ambreen A; Smith, Zachary L; Sendzischew Shane, Morgan A; Aroniadis, Olga C; Ordiah, Collins O; Ruddy, Johannah M; Simren, Magnus; Tack, Jan; Drossman, Douglas.
Afiliação
  • Elmunzer BJ; Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina. Electronic address: elmunzer@musc.edu.
  • Palsson OS; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina.
  • Forbes N; Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Zakaria A; Division of Gastroenterology, Department of Medicine, Ascension Providence Hospital/Michigan State University-College of Human Medicine, Southfield, Michigan.
  • Davis C; Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Canakis A; Section of Gastroenterology, Department of Medicine, Boston University Medical Center, Boston, Massachusetts.
  • Qayed E; Division of Digestive Diseases, Department of Medicine, Grady Memorial Hospital, Atlanta, Georgia.
  • Bick B; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
  • Pawa S; Division of Gastroenterology, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
  • Tierney WM; Section of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • McLeod CG; Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Taylor J; Division of Gastroenterology and Hepatology, Department of Medicine, Saint Louis University, St. Louis, Missouri.
  • Patel H; Department of Gastroenterology, Ochsner Health, New Orleans, Louisiana.
  • Mendelsohn RB; Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bala G; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Sloan I; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Merchant AA; Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
  • Smith ZL; Division of Gastroenterology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Sendzischew Shane MA; Division of Gastroenterology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
  • Aroniadis OC; Division of Gastroenterology, Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
  • Ordiah CO; Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Ruddy JM; Rome Foundation Research Institute and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Simren M; Rome Foundation Research Institute and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Institute of Medicine, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Tack J; Rome Foundation Research Institute and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
  • Drossman D; Rome Foundation Research Institute and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Article em En | MEDLINE | ID: mdl-37995983
ABSTRACT
BACKGROUND &

AIMS:

Acute enteric infections are well known to result in long-term gastrointestinal (GI) disorders. Although COVID-19 is principally a respiratory illness, it demonstrates significant GI tropism, possibly predisposing to prolonged gut manifestations. We aimed to examine the long-term GI impact of hospitalization with COVID-19.

METHODS:

Nested within a large-scale observational cohort study of patients hospitalized with COVID-19 across North America, we performed a follow-up survey of 530 survivors 12-18 months later to assess for persistent GI symptoms and their severity, and for the development of disorders of gut-brain interaction (DGBIs). Eligible patients were identified at the study site level and surveyed electronically. The survey instrument included the Rome IV Diagnostic Questionnaire for DGBI, a rating scale of 24 COVID-related symptoms, the Gastrointestinal Symptoms Rating Scale, and the Impact of Events-Revised trauma symptom questionnaire (a measure of posttraumatic stress associated with the illness experience). A regression analysis was performed to explore the factors associated with GI symptom severity at follow-up.

RESULTS:

Of the 530 invited patients, 116 responded (52.6% females; mean age, 55.2 years), and 73 of those (60.3%) met criteria for 1 or more Rome IV DGBI at follow-up, higher than the prevalence in the US general population (P < .0001). Among patients who experienced COVID-related GI symptoms during the index hospitalization (abdominal pain, nausea, vomiting, or diarrhea), 42.1% retained at least 1 of these symptoms at follow-up; in comparison, 89.8% of respondents retained any (GI or non-GI) COVID-related symptom. The number of moderate or severe GI symptoms experienced during the initial COVID-19 illness by self-report correlated with the development of DGBI and severity of GI symptoms at follow-up. Posttraumatic stress disorder (Impact of Events-Revised score ≥33) related to the COVID-19 illness experience was identified in 41.4% of respondents and those individuals had higher DGBI prevalence and GI symptom severity. Regression analysis revealed that higher psychological trauma score (Impact of Events-Revised) was the strongest predictor of GI symptom severity at follow-up.

CONCLUSIONS:

In this follow-up survey of patients 12-18 months after hospitalization with COVID-19, there was a high prevalence of DGBIs and persistent GI symptoms. Prolonged GI manifestations were associated with the severity of GI symptoms during hospitalization and with the degree of psychological trauma related to the illness experience.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article